http://www.athersys....eleaseID=955434
"We are particularly excited by the one-year follow-up results because they show that MultiStem treatment can significantly increase the number of patients who have an Excellent Outcome, meaning complete or nearly full recovery, over the standard of care when considering all subjects in the trial,"
commented Dr. Gil Van Bokkelen, Chairman & CEO at Athersys.
